1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Haemato AG

Haemato AG

HAEK.DE
Haemato AGDE flagDeutsche Börse
21.40
EUR
-0.40
- -
111.50MMarket Cap
Haemato AG
HAEK.DE
(Deutsche Börse)

Recent

price

21.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
FRC
46.9
14.94
4.48
17.27
7.92
12.35
88.63
97.54
110.56
132.64
134.83
122.27
86.51
99.81
55.94
47.45
Revenue per Share
3.1
4.31
-6.2
4.16
1.08
3.37
4.05
3.36
2.67
5.31
3.24
2.8
-0.51
-2.02
1.28
1.57
Basic EPS, GAAP
11.55
-2.98
-7.4
-0.98
-6.48
-1.97
-15.88
0.44
1.05
5.79
-4.57
-0.26
-1.69
5.79
2.69
3.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
1.67
0.33
1.74
3
3
2.55
3.07
2.94
1
- -
0.54
1.1
Dividend per Share
24.51
28.66
22.57
19.32
18.94
16.15
23.17
22.2
21.86
24.17
24.62
23.82
21.85
11.31
6.33
6.63
Book Value per Share
32.48
31.79
14.29
14.38
17.85
12.53
7.99
8.45
8.7
11.47
14.84
16.5
14.86
36.64
10.5
10.69
Tangible Book Value per Share
1
1
1
1
1
2
2
2
2
2
2
2
2
2
5
5
Basic Weighted Avg Shares
43
14
4
24
11
25
174
203
230
276
289
274
198
238
285
248
Sales/Revenue/Turnover
6.91
28.27
-80.14
24.57
10.94
36.68
5.72
4.06
3.58
4.88
3.24
2.39
-0.01
0.68
3.92
3.34
Operating Margin (%)
- -
- -
1
2
3
1
2
2
2
2
2
1
2
2
1
1
Depreciation Expense
3
4
-6
6
1
7
8
7
6
11
7
6
-1
-5
7
8
Net Income, GAAP
- -
- -
- -
- -
8.02
14.76
6.96
- -
8.11
9.97
13.72
19.16
- -
- -
30.17
21.86
Effective Tax Rate (%)
6.6
28.88
-138.29
24.05
13.64
27.3
4.57
3.44
2.41
4
2.4
2.29
-0.59
-2.03
2.29
3.3
Profit Margin (%)
23
23
1
6
6
17
31
26
17
31
36
35
17
76
44
42
Working Capital
11
15
8
- -
6
5
17
16
12
24
19
- -
1
1
- -
2
LT Debt
30
29
24
29
29
34
58
59
58
63
71
76
72
125
145
147
Total Equity
- -
- -
- -
- -
3.22
20.7
14.4
- -
8.12
12.19
7.84
5.87
- -
- -
5.69
4.33
Return on Invested Capital (%)
- -
- -
- -
- -
6.27
18.94
15.36
- -
9.1
16.2
10.58
10.22
- -
- -
22.4
24.13
Return on Capital (%)
- -
16.27
-24.11
24.17
5.65
23.29
20.32
15.25
12.1
23.08
13.5
11.81
-2.27
-12.55
22.05
24.48
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.71%
18.62%
1.69%
Free Cash Flow
102.71%
8.74%
35.79%
Net Income, GAAP
1.93%
-5.27%
25.39%
Sales/Revenue/Turnover
64.22%
-1.2%
-12.95%
Total Cash Common Dividend
- -
- -
108.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
285
2022
- -
- -
- -
- -
248
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
1.28
2022
- -
- -
- -
- -
1.57
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
0.54
2022
- -
- -
- -
- -
1.1
2023
- -
- -
- -
- -
- -
Similar Companies
Entourage Health Corp. (ENTG.V)
Hybio Pharmaceutical Co., Ltd. (300199.SZ)
Sequent Scientific Limited (SEQUENT.BO)
DongKook Pharmaceutical Co., Ltd. (086450.KQ)
BioNxt Solutions Inc. (BNXT.CN)
Standard Chem & Pharm Co. Ltd. (1720.TW)
Business
Haemato AG is a Germany-based specialty pharmaceutical company founded in 1993 and headquartered in Schönefeld, Germany. The company operates primarily in the pharmaceutical and lifestyle & aesthetics sectors, supplying pharmacies, wholesalers, and clinics mainly in Germany and Austria. Its product portfolio includes prescription drugs and over-the-counter products focusing on high-priced therapies for chronic diseases across therapeutic areas such as HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology. The pharmaceutical offerings comprise patent-protected medicines, biosimilars, generics, narcotic pharmaceuticals including cannabis products, and diagnostic tests. The lifestyle & aesthetics segment encompasses the development, manufacture, and distribution of proprietary brands, including medical cosmetics under its M1 SELECT label, alongside third-party products. Recently, Haemato AG completed the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, a leading European healthcare provider, marking a significant strategic operational shift aimed at focusing the company on drug and medical product trading and expanding its in-house development of innovative medical devices for the beauty market, with first product launches anticipated in the near future. Haemato employs over 60 staff and serves a customer base exceeding 7,000, emphasizing patient needs and healthcare cost reduction in its business model.